Skip to content
Search

Latest Stories

UK sees drop in work visa applications from India

The number of skilled work visa applications from Indian nationals to live and work in the UK has dropped by four per cent this year, Home Office said today, amid the government's tightening of the visa regime.

The UK Home Office found that Indians accounted for 29,800 sponsored visa application in the year ending June 2017.


The trend is being attributed to the UK government's tightening of visa regime in an attempt to meet its goal of cutting migrant figures in the country.

"Indian nationals account for 29,800 (54 per cent) of skilled work sponsored visa applications in year ending June 2017, with US nationals the next largest group (5,686 or 10 per cent of the total)," the Home Office said.

"The number of sponsored visa applications for Indian nationals was 4 per cent lower in year ending June 2017 and applications for US nationals were 9 per cent lower," it said.

However, the data based on the UK's Office of National Statistics (ONS) analysis also disclosed that Indians continue to account for the largest number of skilled work visas granted by the UK government, 53,366 of a total of 92,805 or 58 per cent of all work visas granted.

Of these, the Indian information technology sector sponsored 42 per cent of all skilled work visa applications made by Indians.

The latest ONS figures released today also indicate a so-called "Brexodus", a significant drop in EU nationals migrating to live and work in the UK in the wake of the June 2016 Brexit referendum.

Net migration, the difference between those entering and leaving the UK, fell by 81,000 to 246,000 in the year to March 2017 and more than half that change is due to a decrease in net migration of EU citizens, which is down 51,000.

The ONS figures show a sharp rise of 17,000 in departures of citizens from the so-called EU8 countries - Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.

Also, far fewer EU migrants came to the UK looking for work than before, down 29,000 to 47,000 during the year ending June 2017.

"The net migration change was driven by an increase in emigration, mainly for EU citizens and in particular EU8 citizens, and a decrease in immigration across all groups," said Nicola White, head of international migration statistics at the ONS.

"These results are similar to 2016 estimates and indicate that the EU referendum result may be influencing peoples decision to migrate into and out of the UK, particularly EU and EU8 citizens. It is too early to tell if this is an indication of a long-term trend," White said.

Business leaders have warned that this fall, combined with a fall in skilled migrants from outside the EU, could make it difficult for companies to find the right people for jobs.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less